KNCV applauds new guidance on MDR-TB treatment

KNCV welcomes the new guidance issued by WHO on the treatment of drug resistant TB and applauds this important step towards safer, shorter, injection free regimens for MDR TB patients.

KNCV also supports that all patients have access to rapid molecular resistance testing: the right diagnosis for the right treatment.

For the last several years, KNCV , under the USAID funded Challenge TB project, has supported  over a dozen countries to access rapid molecular testing and deploy new drugs and regimens, including bedaquiline;  these countries now are in a good position to responsibly apply the new guidance with appropriate supportive systems.

Based on this experience, KNCV stands ready to assist any country during their transition.

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.